Literature DB >> 16953276

Antibody profile and clinical course in primary antiphospholipid syndrome with pregnancy morbidity.

Amelia Ruffatti1, Marta Tonello, Teresa Del Ross, Anna Cavazzana, Chiara Grava, Franco Noventa, Francesco Tona, Sabino Iliceto, Vittorio Pengo.   

Abstract

In women diagnosed as having category I primary obstetric antiphospholipid syndrome, clinical characteristics and the risk of subsequent thromboembolic events and further unsuccessful pregnancy has not been clearly documented. Women with unexplained obstetric complications and no definite autoimmune systemic diseases were tested for lupus anticoagulant (LA), IgG/IgM anticardiolipin (aCL) and IgG/IgM anti-human beta2-Glycoprotein I (abeta2GPI) antibodies and diagnosed as having primary antiphospholipid syndrome (APS) in classification category I on the basis of more than one laboratory criteria present in any combination. Characteristics at the time of diagnosis and risk factors for subsequent clinical events during a mean follow-up of 6.3 years were evaluated. Fifty-three of 600 women studied were found to fulfil obstetric criteria and had more than one positive laboratory test at the time of diagnosis. All the women were aCL and abeta2GPI positive, and 16 were also LA positive. This latter group (triple positivity) had distinct features and had more frequently experienced previous thromboembolism (OR = 122.5, 95% CI 16-957, p < 0.001). They also had an increased rate of late pregnancy loss (OR = 16.2, 95%CI 0.9-292, p = 0.01), and a higher IgG abeta2GPI titer at diagnosis (median, 25(th) and 75(th) percentile were 118, 37-962, vs. 23, 18-32, respectively, p < 0.0001). During follow-up, the rate of thromboembolic events was significantly higher in the group of women with triple positivity and/ or previous thromboembolism (OR = 57.5, 95% CI 2.7-1160, p = 0.0004) which were the only independent predictors of TE in the multivariate model. Recurrent pregnancy loss took place in seven out of 47 women who had a new pregnancy. Triple positivity and/or previous thromboembolism were again the only independent markers (OR = 34.4, 95% CI 3.5-335.1, p = 0.003) of an unsuccessful new pregnancy. In conclusion, in primary APS with pregnancy morbidity in classification category I, quite different groups of patients may be identified on the basis of laboratory tests. Triple positivity and/or a history of thromboembolism predict new TE events and new unsuccessful pregnancies.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16953276     DOI: 10.1160/TH06-05-0287

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  26 in total

Review 1.  Recurrent miscarriage, antiphospholipid antibodies and the risk of thromboembolic disease.

Authors:  M Ángeles Martínez-Zamora; Ricard Cervera; Juan Balasch
Journal:  Clin Rev Allergy Immunol       Date:  2012-12       Impact factor: 8.667

2.  Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies.

Authors:  Michael D Lockshin; Mimi Kim; Carl A Laskin; Marta Guerra; D Ware Branch; Joan Merrill; Michelle Petri; T Flint Porter; Lisa Sammaritano; Mary D Stephenson; Jill Buyon; Jane E Salmon
Journal:  Arthritis Rheum       Date:  2012-07

Review 3.  Clinical Risk Assessment in the Antiphospholipid Syndrome: Current Landscape and Emerging Biomarkers.

Authors:  Shruti Chaturvedi; Keith R McCrae
Journal:  Curr Rheumatol Rep       Date:  2017-07       Impact factor: 4.592

4.  APhL antibody ELISA as an alternative to anticardiolipin test for the diagnosis of antiphospholipid syndrome.

Authors:  Brenda B Suh-Lailam; Anndorie Cromar; K Wayne Davis; Anne E Tebo
Journal:  Int J Clin Exp Pathol       Date:  2012-03-25

5.  Top 10 clinical research developments in antiphospholipid syndrome.

Authors:  Medha Barbhaiya; Doruk Erkan
Journal:  Curr Rheumatol Rep       Date:  2013-10       Impact factor: 4.592

6.  Antiphospholipid Syndrome during pregnancy: the state of the art.

Authors:  Fosca A F Di Prima; Oriana Valenti; Entela Hyseni; Elsa Giorgio; Marianna Faraci; Eliana Renda; Roberta De Domenico; Santo Monte
Journal:  J Prenat Med       Date:  2011-04

7.  Role of anticardiolipin antibodies in the pathogenesis of prosthetic valve thrombosis: An observational study.

Authors:  A Ç Aykan; T Gökdeniz; M Kalçık; M A Astarcıoğlu; S Gündüz; S Karakoyun; M O Gürsoy; A E Oğuz; E Ertürk; B Çakal; Z Bayram; M Özkan
Journal:  Herz       Date:  2014-01-19       Impact factor: 1.443

8.  Management of very high risk pregnancy with secondary anti-phospholipid syndrome and triple positivity to the anti-phospholipid antibodies.

Authors:  Hannah L Rose; Wai Khoon Ho
Journal:  J Thromb Thrombolysis       Date:  2014-11       Impact factor: 2.300

9.  Recurrent thrombosis prevention with intravenous immunoglobulin and hydroxychloroquine during pregnancy in a patient with history of catastrophic antiphospholipid syndrome and pregnancy loss.

Authors:  Nataliya Mar; Rebecca Kosowicz; Karen Hook
Journal:  J Thromb Thrombolysis       Date:  2014       Impact factor: 2.300

Review 10.  Additional Treatments for High-Risk Obstetric Antiphospholipid Syndrome: a Comprehensive Review.

Authors:  Amelia Ruffatti; Ariela Hoxha; Maria Favaro; Marta Tonello; Anna Colpo; Umberto Cucchini; Alessandra Banzato; Vittorio Pengo
Journal:  Clin Rev Allergy Immunol       Date:  2017-08       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.